GlassScriptPhysician profile
Romulo Jc Albuquerque
NPI 1265726905
$19,798.00
in general payments reported to CMS, 2019-2025
25 companies · $984 in 2025
The $984 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,849 · 2020: $2,530 · 2021: $2,710 · 2022: $769 · 2023: $1,100 · 2024: $3,856 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,244 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,679 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,678.50 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $10,409.44 | 2019-2025 | Vabysmo |
| Glaukos Corporation | $2,678.50 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3, Kxl System (Not Refurbished), Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Genentech, INC. | $2,385.25 | 2020-2024 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $903.54 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $602.93 | 2022-2025 | Ozurdex |
| Alimera Sciences, INC. | $419.63 | 2021-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $391.15 | 2024-2025 | Izervay |
| Allergan, INC. | $376.57 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $338.05 | 2022-2025 | Xipere, Visudyne |
| Rxsight INC | $314.52 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Apellis Pharmaceuticals, INC. | $236.52 | 2023-2025 | Syfovre |
| Coherus Oncology, INC. | $156.64 | 2022-2023 | |
| Regeneron Pharmaceuticals, INC. | $113.95 | 2025 | Eylea Hd |
| Ani Pharmaceuticals, INC. | $97.27 | 2024-2025 | Iluvien, Yutiq |
| Carl Zeiss Meditec USA, INC. | $55.63 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $54.38 | 2024-2025 | Iheezo, Triesence |
| Biogen, INC. | $52.34 | 2022-2024 | Byooviz |
| Alcon Vision LLC | $48.35 | 2025 | Constellation, Rocklatan |
| Ocular Therapeutix, INC. | $45.02 | 2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.25 | 2021 | |
| Eyepoint US, INC. | $21.43 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.18 | 2020 | |
| Neurotech Pharmaceuticals, INC. | $13.72 | 2025 | |
| Spark Therapeutics, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romulo Albuquerque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.